Back

Eli Lilly and Novo develop amylin drugs for obesity and diabetes

Verifying
  • Eli Lilly and Novo are developing amylin drugs for obesity and diabetes.
  • New injections, pills and combinations target the amylin pathway.
  • Amylin treatments may complement GLP-1 drugs or provide additional options.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.